Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
<div><p>PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk...
Saved in:
| Main Author: | Ghaneya Al-Khadairi (14153274) (author) |
|---|---|
| Other Authors: | Julie Decock (44558) (author) |
| Published: |
2019
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Cancer testis antigens in cancer: Recent developments as cancer biomarkers and therapeutic targets
by: Adviti Naik (673163)
Published: (2022) -
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
by: Afsheen Raza (492657)
Published: (2022) -
Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
by: Remy Thomas (702843)
Published: (2020) -
PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
by: Ghaneya Al-Khadairi (14153274)
Published: (2019) -
Commentary: Cancer-testis antigen lactate dehydrogenase C4 as a novel biomarker of male infertility and cancer
by: A. Naik (7783220)
Published: (2023)